Altimmune, Inc. · NASDAQ:ALT
Altimmune — Q1 2021 Earnings Presentation
13 slides from Altimmune's earnings presentation, May 17, 2021
Slide 1: First Quarter 2021 Results: Corporate Update & Financial Results
First Quarter 2021 Results Corporate Update & Financial Results May 17, 2021 NASDAQ: ALT
Slide 2: Forward-looking statements
2 Forward-looking statements Safe-Harbor Statement This presentation has been prepared by Altimmune, Inc. ("we," "us," "our," "Altimmune" or the "Company") and includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statemen
Slide 3: Agenda
Q&A Corporate Update Vipin K. Garg, Ph.D. – President and Chief Executive Officer Preclinical Update Scot Roberts, Ph.D. – Chief Scientific Officer Clinical Update Scott Harris, M.D. – Chief Medical Officer Q1 Financial Update Will Brown, CPA – Chief Financial Officer Agenda 3
Slide 4: AdCOVID Preclinical Update
©altimmune AdCOVID Preclinical Update
Slide 5: AdCOVID provides sterilizing immunity in mice
AdCOVId provides sterilizing immunity IN Mice Single intranasal dose of AdCOVID administered 28 days prior to SARS-CoV-2 challenge Heavy viral RNA burden reduced ~1000-fold over non-vaccinated controls Infectious virus undetectable in lungs of AdCOVID vaccinated mice (≥50,000-fold reduction in PFU o
Slide 6: Single dose AdCOVID protects against lung disease in mice
SINGLE DOSE AdCOVId Protects against Lung disease in Mice Control AdCOVID Low magnification High magnification 6
Slide 7: AdCOVID Clinical Update
©altimmune AdCOVID Clinical Update
Slide 8: AdCOVID Phase 1 study design
207 days Nov 15 - Aug 30 126 days Nov 10 - May 4 110 days May 15 - Oct 15 78 days Jun 15 - Sep 30 67 days Jul 15 - Oct 15 185 days Oct 15 - Jun 30 AMENDED AdCOVID Phase 1 study design Approximately 80 subjects randomized 5:1 to receive one or two doses of AdCOVID or placebo Three dose groups Low dos
Slide 9: Key anticipated Phase 2 trials and target product profile
Naïve and previously-infected populations in Low-Access Countries Revaccination with parental and variant vaccines in previously vaccinated individuals Age-based de-escalation study in young children and adolescents Maternal immunization study Boosts natural immune response to wild-type and variant
Slide 10: ALT-801 Clinical Update
©altimmune ALT-801 Clinical Update
Slide 11: ALT-801 Phase 1 trial update
ALT-801 Phase 1 trial update 11 Phase 1 study is advancing to study readout Enrollment completed in the single ascending dose (SAD) phase and the 3 planned cohorts of multiple ascending dose (MAD) phase of the trial 6-week data anticipated in June 2021; 12-week data anticipated in Q3 2021 Anticipate
Slide 12: ALT-801 potential IND filing for obesity in 2H 2021
ALT-801 – Potential ind filing for obesity in 2h 2021 12 Novo Nordisk (semaglutide) and Lilly (tirzepatide) have executed successful Phase 3 programs; these have de-risked the obesity space previously occupied by unsafe and ineffective drugs GI intolerability has been the Achilles heel for GLP-1 bas
Slide 13: First Quarter 2021 Results & Financial Results
First Quarter 2021 Results Corporate Update & Financial Results May 17, 2021 NASDAQ: ALT